Menu

IMPORTANT CME CREDIT NOTICE

CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed. Surveys are accessible after logging in with the email address you submitted during registration.

Surveys will be accessible online the day of the symposium and for 3 weeks following. You must complete the process by June 30, 2025 in order to receive your certificate. Certificates will be available online until December 1, 2024 and are printable directly from the website.


ACCREDITATION

The AAFP will review 8th Annual Symposium Contemporary Management of Cardiovascular Disease in Women and designate credit hours at a later date.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.


COURSE DESCRIPTION

Heart disease is the leading cause of death in women in the US and accounts for more deaths each year than all of the other causes combined. The rates of death are even higher in women of racial or ethnic minority. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of a heart attack. Compared to men, women are less likely to receive standard of care of treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to educate healthcare providers about the impact of cardiovascular disease on women and empower them to be advocates for women's cardiovascular health.

This educational symposium will review the current epidemiology of cardiovascular disease in women, and examine women–specific cardiovascular issues related to diagnosis and treatment. Cardiovascular risk factors and diseases more common in women will be examined, including stress and ischemia without obstructive CAD. In addition, cardiac-specific risk stratification during reproductive years, an update on lipid therapies, and peripartum cardiomyopathy will be discussed. Sex specific differences in the management of congestive heart failure and cardiac arrhythmias will be reviewed with emphasis on sex-specific differences and considerations. State of the art therapies for deep vein thrombosis/pulmonary embolism, resistant hypertension and percutaneous treatments of valvular heart disease will be included, with an emphasis on gender-specific outcomes. This year will include a look into the current representation of women in the cardiovascular work-force and its implication on cardiovascular outcomes in women patients. Finally, cased-based presentations will highlight ongoing dilemmas in cardiovascular management, and the use of novel pharmaceutical agents and invasive techniques.

The objective of this symposium is to educate healthcare providers on gender-specific approaches in prevention, diagnosis, and treatment of women with a broad range of cardiovascular diseases.


PROGRAM OBJECTIVES

The overall objectives are to:

  1. Review and understand the current epidemiology of cardiovascular disease in women.
  2. Educate the practitioner on the risk factors of cardiovascular disease more common in women that are oftentimes overlooked.
  3. Review the current guidelines for the management of cardiovascular disease, congestive heart failure, atrial fibrillation, and peripheral vascular disease with an emphasis on sex-specific outcomes.
ADDITIONAL FOCUS FOR ATTENDEES:
NEEDS ASSESSMENT

Heart disease is the leading cause of death in women in the U.S. and accounts for more deaths each year than all of the other causes combined. In women of racial or ethnic minority the rates of death are even higher. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of a heart attack. Compared to men, women are less likely to receive standard of care of treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to educate healthcare providers about the impact of cardiovascular disease on women and empower them to be advocates for women's cardiovascular health.


TARGET AUDIENCE

This program has been designed to provide primary care physicians, internists, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists and other healthcare providers with the necessary information to increase knowledge and awareness of cardiovascular disease in women with the goal of improving patient care.


CULTURAL AND LINGUISTIC COMPENTENCY AUDIENCE

This activity is in compliance with California Assembly Bills 1195 and 241 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient’s primary language. Cultural and linguistic competency was incorporated into the planning of this activity.


FACULTY DISCLOSURE

It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity.


FURTHER INFORMATION

Complete Conference Management
3320 Third Avenue, Suite C
San Diego, CA  92103

Phone 619-299-6673
Fax 619-299-6675
info@ccmmeetings.com

> www.ccmmeetings.com